Mary Beth Nierengarten

Advanced Treatment Options for Men with Low-Risk Prostate Cancer

09/19/2013

Results of a retrospective cohort study show that the use of advanced treatment technologies for men with prostate cancer with low-risk disease, those at high risk of noncancer mortality, or men with both low-risk disease and at high risk of...

Results of a retrospective...

09/19/2013

First Report Managed Care

Cardiovascular Risk in Patients with Rheumatoid Arthritis

03/16/2012

Mary Beth Nierengarten ;

Chicago—In patients with rheumatoid arthritis (RA), the length of disease duration does not appear to aggravate or contribute to cardiovascular risk, but very low disease activity sustained over time may actually have a beneficial effect on...

Chicago—In patients with...

03/16/2012

First Report Managed Care

Conference Insider

Ustekinumab for Patients with Active PsA Long-Term

02/19/2014

Mary Beth Nierengarten ;

San Diego—The efficacy and safety of ustekinumab as treatment for active psoriatic arthritis (PsA) is maintained at 100 weeks follow-up, according to long-term data presented at the ACR/ARHP meeting.

San Diego—The efficacy and...

02/19/2014

First Report Managed Care

Feature

Countering Misinformation in Medicine

05/20/2022

Mary Beth Nierengarten ;

Medical misinformation is a growing challenge throughout health care, exacerbated by the ubiquitous use of social media that reinforces people’s tendencies to perceive and believe in things supported by other people.

Medical misinformation is a...

05/20/2022

First Report Managed Care

News

The Promise of Oral Insulin: Improving Adherence and Impacting Diabetes Outcomes

07/11/2018

Mary Beth Nierengarten ;

In order to better understand how the introduction of oral insulin will impact managing patients with type 2 diabetes, we spoke with two diabetes experts about the need to improve treatment and the potential role of oral insulin to help...

In order to better understand...

07/11/2018

First Report Managed Care

Adverse Outcomes for Nonobstructive Coronary Artery Disease

02/17/2015

Mary Beth Nierengarten ;

In a study, researchers evaluated the hypothesis of an association between increasing coronary artery disease (CAD) across the continuum of nonobstructive and obstructive CAD with increasing rates of myocardial infarction and all-cause...

In a study, researchers...

02/17/2015

First Report Managed Care

Anti-TNF Drugs to Treat Rheumatoid Arthritis

02/14/2013

Mary Beth Nierengarten ;

Washington, DC—For patients with rheumatoid arthritis (RA), treatment with anti-tumor necrosis factor (anti-TNF) drugs may reduce the need for hip or knee surgeries as well as the need for hospital admissions. Despite the higher costs of...

Washington, DC—For patients with...

02/14/2013

First Report Managed Care

Feature

Long-Term Treatment with Asenapine Safe and Effective for Schizophrenia and Schizoaffective Disorder

06/28/2010

Mary Beth Nierengarten ;

New Orleans—An extension study that looked at the safety and efficacy of asenapine to treat patients with schizophrenia or schizoaffective disorder found that asenapine remains well tolerated and effective for up to 3 years of treatment. The...

New Orleans—An extension study...

06/28/2010

First Report Managed Care

News Connection

Surgery for Initial Treatment of Moderate-to-Severe Stress UI

12/17/2013

Mary Beth Nierengarten ;

Results of multicenter, randomized trial show that women with moderate-to-severe stress urinary incontinence (UI) treated by surgery have higher rates of subjective and objective outcomes at 1 year compared with women treated by initial...

Results of multicenter,...

12/17/2013

First Report Managed Care

Orphan Drugs: Rare Disease Treatments Becoming Commonplace

10/20/2016

Mary Beth Nierengarten ;

As the popularity of rare-disease indicated orphan drugs increases, payers are becoming concerned about whether or not these prescriptions are entirely necessary.

As the popularity of...

10/20/2016

First Report Managed Care